Product Name:(1R,3r,6s,8S)-4-oxatricyclo[4.3.1.13,8]undecan-5-one

IUPAC Name:(1R,3r,6s,8S)-4-oxatricyclo[4.3.1.1³,⁸]undecan-5-one

CAS:21898-84-0
Molecular Formula:C10H14O2
Purity:95%
Catalog Number:CM128288
Molecular Weight:166.22

Packing Unit Available Stock Price($) Quantity
CM128288-1g 1-2 Weeks ŪȖȯŪ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:21898-84-0
Molecular Formula:C10H14O2
Melting Point:-
Smiles Code:O=C1O[C@@]2([H])C[C@]3([H])C[C@@](C2)([H])C[C@@]1([H])C3
Density:
Catalog Number:CM128288
Molecular Weight:166.22
Boiling Point:297.6°C at 760 mmHg
MDL No:MFCD00184584
Storage:Store at 2-8°C.

Category Infos

Bridged Compounds
Bridged ring compound refers to any two rings in the compound, which share two non-directly connected carbon atoms, and are classified into bicyclic hydrocarbons, tricyclic hydrocarbons, tetracyclic hydrocarbons, etc. Carbon atoms used in two or more rings are bridgehead carbon atoms, and the bond connecting the bridgehead carbon atoms is called a bridge. Bridged ring compounds are a class of organic compounds that are widely present in nature and usually have important physiological activities, such as the famous anticancer drug paclitaxel and antimalarial drug artemisinin.
bridged compounds,bridged bicyclic compounds
Buy low price, high quality bridged compounds and bridged bicyclic compounds,choose our products,Chemenu is the leading factory & company. Warmly welcome new and old customers to visit and patronize!
Cyclohexanes
Cyclohexane is an organic compound with a chemical formula C6H12. It is a colorless liquid with a pungent odor, insoluble in water, and soluble in most organic solvents such as ethanol, ether, benzene, and acetone. Cyclohexyl fragments are a common structure in both natural and synthetic drugs. It can be used as both core structure and part of achiral side chain.

Column Infos

Sunobinop
Sunobinop is an investigational, novel and potential first-in-class oral compound discovered by Imbrium Therapeutics and that is currently in clinical development. Sunobinop is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions, including bladder function.
As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.